Despite the prominent role of MMP-9 and MMP-3 in BBB disruption in cerebral ischemia, therapeutic targeting of these proteases in humans is challenging because current pharmacological inhibitors produce a complete and unspecific inhibition of all members of the MMP family which results in unfavorable side effects and limits their clinical use61. This evidence concerns the gene MMP3 and brain ischemia.